DALLAS, March 11, 2025 /PRNewswire/ -- ATI Inc. (NYSE: ATI) is unhappy to report that one of the two votes to approve a labor agreement did not pass. The employees of ATI's Specialty Rolled Products in Western Pennsylvania and Lockport, New York, along with the United Steelworkers (USW), were unable to ratify a new labor agreement.
In the most recent trading session, Allegheny Technologies (ATI) finished at $57.24, which is a decrease of 1.05% compared to the previous day.
DOWNERS GROVE, Ill., March 4, 2025 /PRNewswire/ -- ATI Physical Therapy, Inc. (OTCMKTS: ATIP) ("ATI" or the "Company"), a well-known outpatient physical therapy provider in the U.S., announced that it completed a $26 million financing of 8% second lien PIK convertible notes on March 3, 2025.
Are you looking for ways to choose powerful stocks that can outperform the market for your investment portfolio? The Zacks Style Scores can help you with that.
DALLAS, Feb. 28, 2025 /PRNewswire/ -- ATI Inc. (NYSE: ATI) has announced that they have reached a preliminary agreement with the United Steelworkers (USW) for a new six-year Master Contract. This agreement will be submitted to the USW general members for their approval votes.
Appili Therapeutics Inc. received strong support from shareholders for its plan to go private with Aditxt. The company is working with regulatory authorities on its ATI-1801 program and is preparing to submit ATI-1701 for Investigational New Drug approval. Additionally, Appili has strengthened its partnerships with the government, solidifying its role in biodefense and solutions for infectious diseases.
ATI's new additive manufacturing facility features the largest format in the industry and has the most advanced capabilities.
ATI Inc. has opened a top-notch Additive Manufacturing Products facility in Margate, Florida, which features the largest and most advanced metal additive manufacturing technology available. This new facility was officially launched on February 13, 2025.
Aclaris Therapeutics, Inc. has released a new publication highlighting the special features of their investigational drug, ATI-2138. This drug is a covalent inhibitor targeting interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3), and it is being developed to treat autoimmune and inflammatory diseases. The data generated so far suggests that ATI-2138 could have a significant impact on various human inflammatory conditions.
On February 6, 2025, Allegheny Health Network announced that it experienced a data breach, which affected the private personal and health information of many people. This incident has raised worries about the safety of the sensitive information that individuals have shared with AHN. What does this mean?